SEATTLE and VANCOUVER, British Columbia, May 30, 2019 /PRNewswire/ -- Achieve Life
Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical
company committed to the global development and commercialization
of cytisinicline for smoking cessation, today announced that the
United States Patent and Trademark Office has granted Achieve a
patent (No. 10,300,050) on succinate salt of cytisinicline and use
thereof.
"It is particularly important as we advance the cytisinicline
clinical development program that we continue to expand our
intellectual property portfolio through patent extensions to
protect the value associated with our smoking cessation
franchise," stated Rick
Stewart, Chairman and Chief Executive Officer of
Achieve.
The patent covers a novel salt form of cytisinicline, namely
cytisinicline succinate, and pharmaceutical compositions and dosage
forms. The U.S. Patent follows the grant of the same invention in
the United Kingdom. Applications
are pending in the European Patent Office, Japan, China,
Australia, Canada, and South
Korea.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. Achieve has been
pursuing cytisinicline succinate salt as a novel new drug product
formulation that may further enhance cytisinicline product
stability and long-term potency.
About Cytisinicline
Achieve's focus is to address the global smoking health epidemic
through the development and commercialization of cytisinicline.
Cytisinicline is a plant-based alkaloid with a high binding
affinity to the nicotinic acetylcholine receptor. It is believed to
aid in smoking cessation by interacting with nicotine receptors in
the brain by reducing the severity of nicotine withdrawal symptoms
and by reducing the reward and satisfaction associated with
smoking. As an approved, branded product in Central and
Eastern Europe for more than two
decades, it is estimated that over 20 million people have used
cytisinicline to help combat nicotine addiction.
Tobacco use is currently the leading cause of preventable death
and is responsible for nearly seven million deaths annually
worldwide1. It is estimated that 28.7% of cancer deaths
in the U.S. are attributable to cigarette smoking2.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the planned
cytisinicline clinical development activities, the timing of
clinical development activities related to cytisinicline, the
potential market size for cytisinicline and the potential
benefits of cytisinicline. All statements other than statements of
historical fact are statements that could be deemed forward-looking
statements. Achieve may not actually achieve its plans or product
development goals in a timely manner, if at all, or otherwise carry
out its intentions or meet its expectations or projections
disclosed in these forward-looking statements. These statements are
based on management's current expectations and beliefs and are
subject to a number of risks, uncertainties and assumptions that
could cause actual results to differ materially from those
described in the forward-looking statements, including, among
others, the risk that cytisinicline may not demonstrate the
hypothesized or expected benefits; the risk that Achieve may not be
able to obtain additional financing to fund the development of
cytisinicline; the risk that cytisinicline will not receive
regulatory approval or be successfully commercialized; the risk
that new developments in the smoking cessation landscape require
changes in business strategy or clinical development plans; the
risk that Achieve's intellectual property may not be adequately
protected; general business and economic conditions; and the other
factors described in the risk factors set forth in Achieve's
filings with the Securities and Exchange Commission from time to
time, including Achieve's Annual Reports on Form 10-K and Quarterly
Reports on Form 10-Q. Achieve undertakes no obligation to update
the forward-looking statements contained herein or to reflect
events or circumstances occurring after the date hereof, other than
as may be required by applicable law.
Achieve Contact
Jason Wong
jwong@bplifescience.com
(415) 375-3340 ext. 4
1 World Health Organization. WHO Report on the Global
Tobacco Epidemic, 2017. Geneva:
World Health Organization, 2017
2 Annals of Epidemiology , Volume 25 , Issue 3 ,
179 - 182.e1
View original content to download
multimedia:http://www.prnewswire.com/news-releases/achieve-announces-patent-granted-in-the-us-for-novel-formulation-of-cytisinicline-300858839.html
SOURCE Achieve Life Sciences, Inc.